EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections

Cristina Maria de Barros, Vanja Maria Veloso, Margareth Spangler Andrade, José Mário Carneiro Vilela, Maria Alice de Oliveira, Marta de Lana iD, Maria Terezinha Bahia, Vanessa Carla Furtado Mosqueira iD

Pathogens · 2025

DOI: 10.3390/pathogens14040319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Cristina Maria de Barros und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Pr…. Hauptthemen laut MEDLINE: Chagas Disease, Trypanosoma cruzi, Nanocapsules, Trypanocidal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic management of Chagas disease requires new medicines because the standard-of-care drugs available induce adverse effects and have limited efficacy. In this study, we developed a formulation of albaconazole (ABZ) loaded in biodegradable polymeric nanocapsules (NCs). Free ABZ and ABZ-loaded NCs were similarly active against the Y strain and inactive against the Colombian strain epimastigotes of Trypanosoma cruzi. Infected mice were given ABZ in different doses and treatment schedules by oral, SC, and IM routes during the acute phase of infection. Free ABZ taken orally reduced parasitemia and suppressed mortality; however, all the animals maintained patent parasitemia during and after treatment. ABZ-NCs increased anti-T. cruzi effects (p < 0.05), inducing negative parasitemia during treatment in most of the tested regimens. The parasitemia level was also significantly reduced after treatment with ABZ-NCs during the acute phase of the disease, and relapses were delayed compared with the free ABZ treatment. Once- and twice-daily doses were similarly effective, demonstrating that the NCs prolonged the ABZ-NC residence time. Free ABZ and ABZ-NCs did not prevent infection, ABZ seemed to have suppressive effects on T. cruzi growth, and encapsulation prolonged this suppression. The analysis of the in vivo results indicated that the NCs significantly improved the safety of ABZ in the mouse model, suggesting that the increased ABZ-NC dosage regimen merits further efficacy and pharmacokinetic evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanosoma cruziNanocapsulesTrypanocidal AgentsAnimalsMiceParasitemiaDisease Models, AnimalPolymersFemale

Stichwörter der Autor:innen

UR-9825albaconazoledosage regimendose–responseefficacyformulationnanoparticlestoxicity

Substanzen

NanocapsulesTrypanocidal AgentsPolymers

Autor:innen und Institutionen

  • Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil.
  • Post-Graduation Program in Biological Sciences (NUPEB), Exact and Biological Sciences Institute (ICEB), Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.
  • Department of Pharmacy, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.
  • Laboratory of Nanoscopy, FIEMG SENAI Technological Center-Regional Department of Minas Gerais, Belo Horizonte 31035-536, MG, Brazil.
  • Department of Clinical Analysis, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.
  • Parasitic Diseases Laboratory, School of Medicine, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.

ORCID-Profile: Marta de Lana, Vanessa Carla Furtado Mosqueira

Förderung

  • World Health Organization
  • UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases

Zitieren

APA

de Barros, C. M., Veloso, V. M., Andrade, M. S., Vilela, J. M. C., de Oliveira, M. A., de Lana, M., Bahia, M. T., & Mosqueira, V. C. F. (2025). Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections. Pathogens. https://doi.org/10.3390/pathogens14040319

Vancouver

de Barros CM, Veloso VM, Andrade MS, Vilela JMC, de Oliveira MA, de Lana M, et al. Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections. Pathogens. 2025. doi:10.3390/pathogens14040319

BibTeX
@article{deBarros2025,
  author = {de Barros, Cristina Maria and Veloso, Vanja Maria and Andrade, Margareth Spangler and Vilela, José Mário Carneiro and de Oliveira, Maria Alice and de Lana, Marta and Bahia, Maria Terezinha and Mosqueira, Vanessa Carla Furtado},
  title = {Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14040319}
}
Kostenlos starten →